Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis

Author:

Hu Ke1,Jiang Pin2,song Bing3,Hou Ya4,Gu Qianyu4,Guo Meng4,Peng Ningxin3,Chen Jiayu3,Zhao Jinxuan4,Chen Haiting3,Xie Jun1

Affiliation:

1. The Affiliated Drum Tower Hospital of Nanjing Medical University, Jiangsu,Nanjing, 210008, China

2. Department of General Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, 230022,China

3. Department of Cardiology, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, 230022, China

4. Department of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, MOE Key Laboratory of Model Animal for Disease Study, Nanjing University, Jiangsu,

Abstract

Abstract

Lipopolysaccharide induces sepsis in vivo, with a significant proportion of septic patients progressing to septic cardiomyopathy. Previous studies have reported the involvement of ferroptosis in the pathogenesis of septic cardiomyopathy. SGLT2 inhibitors such as dapagliflozin have been demonstrated to have cardioprotective effects, with reports indicating a reduction in myocardial ischemia-reperfusion injury through the attenuation of ferroptosis. However, the role of ferroptosis-induced myocardial injury in the context of LPS-induced sepsis remains unclear. Therefore, our study aims to investigate the therapeutic effects of dapagliflozin on LPS-induced iron-overload cardiac injury. Our results indicate that dapagliflozin inhibits the translation of key proteins associated with ferroptosis, including GPX4, FTH1, and SLC7A11, while reducing the transcription of lipid peroxidation-related mRNAs PTGS2 and ACSL4, as well as iron metabolism genes TFRC and HMOX1. Additionally, both compounds alleviate potential mitochondrial membrane damage. Furthermore, dapagliflozin has been shown to mitigate LPS-induced cardiac injury burden. Based on these findings, we conclude that dapagliflozin can alleviate LPS-induced iron dysregulation-mediated cardiac dysfunction, expanding the clinical indications for SGLT2 inhibitors.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3